Blood test ( DrugBank: - )

6 diseases

36. 表皮水疱症

臨床試験数 : 160 / 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03730584 (ClinicalTrials.gov)	February 27, 2017	2/11/2018	Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa	Evaluation of the Efficacy of a Topical Analgesic Treatment With ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa	Epidermolysis Bullosa	Drug: Ropivacaine;Biological: Blood test	Assistance Publique - Hôpitaux de Paris	NULL	Completed	N/A	21 Years	All	10	N/A	France

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04746313 (ClinicalTrials.gov)	March 1, 2021	8/2/2021	Prevalence of Hyperprolactinemia in Systemic Scleroderma	Assessment of the Prevalence of Hyperprolactinemia in Systemic Scleroderma	Sclerosis, Systemic;Scleroderma;Hyperprolactinemia	Biological: blood test	University Hospital, Lille	Association pour la Formation et la Recherche en Médecine Interne (AFORMI)	Recruiting	18 Years	N/A	All	200		France

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01317134 (ClinicalTrials.gov)	July 2010	15/3/2011	Endothelial Function in Patients With Pulmonary Arterial Hypertension	Serological and Non-invasive Evaluation of Endothelial Function in Patients With Pulmonary Arterial Hypertension	Hypertension, Pulmonary;Pulmonary Arterial Hypertension;Pathophysiology;Genetics	Device: EndoPAT measurement;Biological: Blood Test	Universitätsklinikum Hamburg-Eppendorf	Pfizer;Actelion	Active, not recruiting	18 Years	N/A	Both	90	N/A	Germany

臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01970735 (ClinicalTrials.gov)	October 2013	23/10/2013	Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2	Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2	Muscular Dystrophy, Facioscapulohumeral	Biological: Blood test	Centre Hospitalier Universitaire de Nice	NULL	Recruiting	18 Years	75 Years	Both	100	N/A	France

臨床試験数 : 83 / 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03926377 (ClinicalTrials.gov)	April 2019	15/4/2019	Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid	Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid	Osteoporosis;Bullous Pemphigoid	Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate	Centre Hospitalier Universitaire, Amiens	University Hospital, Rouen	Not yet recruiting	18 Years	N/A	All	50	Phase 4	NULL

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03492567 (ClinicalTrials.gov)	April 25, 2018	3/4/2018	Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.	Study of Circulating Monocytes as Predictive Biomarker of Osteoclastogenesis in Cystic Fibrosis-related Bone Loss. Impact of CFTR Correctors.	Cystic Fibrosis	Biological: Blood test	Assistance Publique - Hôpitaux de Paris	Vaincre la Mucoviscidose	Completed	18 Years	N/A	All	25	N/A	France
2	NCT00572975 (ClinicalTrials.gov)	August 2006	11/12/2007	Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea	MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea	Cystic Fibrosis;Pancreatic Insufficiency	Other: Pentadecanoic acid (PA) and Triheptadecanoin (THA)	Children's Hospital of Philadelphia	Solvay Pharmaceuticals	Completed	8 Years	N/A	Both	9	Phase 4	United States